[go: up one dir, main page]

KR970705563A - 항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent) - Google Patents

항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent)

Info

Publication number
KR970705563A
KR970705563A KR1019970701213A KR19970701213A KR970705563A KR 970705563 A KR970705563 A KR 970705563A KR 1019970701213 A KR1019970701213 A KR 1019970701213A KR 19970701213 A KR19970701213 A KR 19970701213A KR 970705563 A KR970705563 A KR 970705563A
Authority
KR
South Korea
Prior art keywords
purin
cyclopentene
compound
cyclopropylamino
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019970701213A
Other languages
English (en)
Other versions
KR100376240B1 (ko
Inventor
수산 메리 달루지
제프리 더글라스 윌슨
Original Assignee
그래함 브레레톤
더 웰컴 파운데이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그래함 브레레톤, 더 웰컴 파운데이션 리미티드 filed Critical 그래함 브레레톤
Publication of KR970705563A publication Critical patent/KR970705563A/ko
Application granted granted Critical
Publication of KR100376240B1 publication Critical patent/KR100376240B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)

Abstract

본 발명은 (1S, 4R)-시스-4-[2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일]-2-시클로펜텐-1-메탄올의 숙시에이트 염 또는 그의 용매화물, 상기 화합물을 함유하는 제약 조성물. 의학적 치료에서의 상기 화합물 또는 제약 조성물의 용도, 또는 특히 인체 면역결핍증 바이러스(HIV) 및 간염 B 바이러스(HBV) 감염에 대한 바이러스 질환의 치료 또는 예방 방법에 관한 것이다.

Description

항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트 (4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. (1S, 4R)-시스-4-[2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일]-2-시클로펜텐-1-메탄올의 숙시에니트 염.
  2. 제1항에 청구된 화합물의 용매화물.
  3. 제1항에 청구된 화합물의 수화물.
  4. 제1항에 청구된 화합물의 유효량을 바이러스 감염된 사람에게 투여하는 것으로 이루어지는, 상기 숙주에서의바이러스 감염의 치료 또는 예방 방법.
  5. 의학적 치료에 사용하기 위한 제1항 내지 제3항중 어느 한 항에 청구된 화합물.
  6. 바이러스 감염의 치료 또는 예방을 위한 약제 제조에 있어서의 제1항 내지 제3항중 어느 한 항에 청구된 화합물의 용도.
  7. (1S, 4R)-시스-4-[2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일]-2-시클로펜텐-1-메탄올을 적합한 용매중에서 제1항의 화합물이 형성되도록 하는 조건하에 물 중의 숙신산과 혼합하는 것으로 이루어지는 제1항에 청구된 화합물의 제조 방법.
  8. 제1항 내지 제3항 중 어느 한 항에 청구된 화합물 및 적어도 1종의 제약적으로 허용되는 담체로 이루어지는 제약 조성물.
  9. 제8항에 있어서, 정제 또는 캡슐제 형태를 갖는 제약 조성물.
  10. 제8항에 있어서, 비경구 투여에 적합한 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701213A 1994-08-26 1995-08-25 항바이러스제로서의4-(2-아미노-6-(시클로프로필아미노)-9h-푸린-9-일)-2-시클로펜텐-1-메탄올숙시네이트 Expired - Lifetime KR100376240B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417249.1 1994-08-26
GB9417249A GB9417249D0 (en) 1994-08-26 1994-08-26 A novel salt

Publications (2)

Publication Number Publication Date
KR970705563A true KR970705563A (ko) 1997-10-09
KR100376240B1 KR100376240B1 (ko) 2003-06-11

Family

ID=10760434

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701213A Expired - Lifetime KR100376240B1 (ko) 1994-08-26 1995-08-25 항바이러스제로서의4-(2-아미노-6-(시클로프로필아미노)-9h-푸린-9-일)-2-시클로펜텐-1-메탄올숙시네이트

Country Status (23)

Country Link
EP (1) EP0777669B1 (ko)
JP (1) JPH10505593A (ko)
KR (1) KR100376240B1 (ko)
CN (1) CN1051550C (ko)
AT (1) ATE220067T1 (ko)
AU (1) AU702618B2 (ko)
BR (1) BR9508629A (ko)
CA (1) CA2198010C (ko)
DE (1) DE69527294T2 (ko)
DK (1) DK0777669T3 (ko)
ES (1) ES2179110T3 (ko)
FI (1) FI120403B (ko)
GB (1) GB9417249D0 (ko)
HU (1) HU221302B1 (ko)
IL (1) IL115074A (ko)
MX (1) MX9701273A (ko)
NO (1) NO315200B1 (ko)
NZ (1) NZ291862A (ko)
PT (1) PT777669E (ko)
RU (1) RU2145324C1 (ko)
SI (1) SI0777669T1 (ko)
WO (1) WO1996006844A1 (ko)
ZA (1) ZA957166B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
WO1998052570A1 (en) * 1997-05-17 1998-11-26 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
JP2001525840A (ja) * 1997-05-17 2001-12-11 グラクソ、グループ、リミテッド 炭素環式ヌクレオシド１５９２ｕ８９を含有する抗ウイルス的組合せ
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
SK284594B6 (sk) * 1997-11-27 2005-07-01 Lonza Ag Spôsob výroby derivátov aminoalkoholov a ich soli
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
GB9903091D0 (en) 1999-02-12 1999-03-31 Glaxo Group Ltd Therapeutic nucleoside compound
WO2003011221A2 (en) 2001-07-30 2003-02-13 University Of Southern California PREPARATION AND USE OF α-KETO PHOSPHONATES
WO2005044264A1 (en) * 2003-10-27 2005-05-19 Merck & Co., Inc. Ccr-2 antagonist salt
EP2305680A3 (en) * 2009-09-30 2011-05-18 Aurobindo Pharma Limited Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
CN103282369A (zh) 2011-04-08 2013-09-04 劳乐斯实验室私营有限公司 抗逆转录病毒化合物与抗氧化酸的固体形式、其制备方法以及其药物组合物
JP6391561B2 (ja) 2013-02-27 2018-09-19 国立大学法人京都大学 がんの予防または治療用医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3025492A1 (de) * 1980-07-04 1982-02-04 Siemens AG, 1000 Berlin und 8000 München Filterelement fuer die optische nachrichtentechnik
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate

Also Published As

Publication number Publication date
CN1051550C (zh) 2000-04-19
ES2179110T3 (es) 2003-01-16
FI120403B (fi) 2009-10-15
AU3350995A (en) 1996-03-22
CA2198010A1 (en) 1996-03-07
IL115074A (en) 1998-10-30
AU702618B2 (en) 1999-02-25
EP0777669A1 (en) 1997-06-11
ATE220067T1 (de) 2002-07-15
DE69527294D1 (en) 2002-08-08
ZA957166B (en) 1997-02-25
WO1996006844A1 (en) 1996-03-07
DE69527294T2 (de) 2003-02-13
SI0777669T1 (en) 2002-12-31
KR100376240B1 (ko) 2003-06-11
NO970847D0 (no) 1997-02-25
FI970786A0 (fi) 1997-02-25
HUT77222A (hu) 1998-03-02
CA2198010C (en) 2006-05-02
PT777669E (pt) 2002-11-29
FI970786L (fi) 1997-02-25
CN1156456A (zh) 1997-08-06
DK0777669T3 (da) 2002-10-28
GB9417249D0 (en) 1994-10-19
NZ291862A (en) 1998-02-26
JPH10505593A (ja) 1998-06-02
MX9701273A (es) 1997-05-31
BR9508629A (pt) 1997-11-25
EP0777669B1 (en) 2002-07-03
HU221302B1 (en) 2002-09-28
IL115074A0 (en) 1995-12-08
NO315200B1 (no) 2003-07-28
RU2145324C1 (ru) 2000-02-10
NO970847L (no) 1997-02-25

Similar Documents

Publication Publication Date Title
WO1998056761A3 (en) Benzimidazole derivatives
MY128463A (en) 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
KR970705563A (ko) 항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent)
JP2002528502A5 (ko)
RU95117097A (ru) ПРИМЕНЕНИЕ ДИДЕЗОКСИ-АНАЛОГОВ НУКЛЕОЗИДОВ ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ, СПОСОБ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ, β -Z-5-ФТОР-2',3'-ДИДЕЗОКСИЦИТОЗИН И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ ПРОИЗВОДНЫЕ
CA2373833A1 (en) Medicinal compositions for preventing or treating viral myocarditis
DE69333723D1 (de) Pharmazeutische zubereitung auf der basis von rhamnolipid gegen dermatologische erkrankungen
RU97104483A (ru) Соль янтарной кислоты 4-[2-амино-6-(циклопропиламино)-9н-пурин-9-ил]-2- циклопентен-1-метанола в качестве антивирусного агента
JP2648329B2 (ja) エイズの予防または治療用医薬組成物
ES2105923A1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
KR900001697A (ko) 치료용 화합물
KR910018393A (ko) 항바이러스제로서의 비대칭 2-(포스포노메톡시)프로필 구아닌
KR900701278A (ko) 바이러스 감염 치료용 담즙산
ES2148234T3 (es) Composicion farmaceutica a base de flavopereirina y su utilizacion en el tratamiento del virus vih.
JP2007297412A (ja) ヒト・ヘルペスウイルス−８の治療に対するペンシクロビルの使用
US4537908A (en) Herpes II treatment
JPH10501217A (ja) Ｈｉｖの被爆後阻止
JPH08208502A (ja) 抗エイズウイルス剤の効果増強剤
DE60022047D1 (de) Antivirale therapie
JPH03251526A (ja) 糖尿病依存型自己免疫疾患治療、予防用薬剤
JPH01163121A (ja) 抗レトロウイルス剤
JPH06506673A (ja) Ｈｉｖ−１感染の治療におけるグアニン誘導体またはそのプロドラッグの使用
JPS5462327A (en) Remedy for dna virus infectious disease
JPH02145517A (ja) エイズ発症防止、治療剤及び該治療用組成物
JPH03206050A (ja) 医薬組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19970225

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20000825

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20020827

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20030127

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20030304

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20030305

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20060113

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20070112

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20080117

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20090121

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20100122

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20110225

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20120228

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20130227

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20140227

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20140227

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20150227

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20150227

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term